SpreadEx Limited Form 8.3 - Midatech Pharma PLC (9560Q)
24 June 2020 - 9:01PM
UK Regulatory
TIDMMTPH
RNS Number : 9560Q
SpreadEx Limited
24 June 2020
Michael Hennigan - Form 8.3 - Midatech Pharma plc
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Michael Hennigan
(b) Owner or controller of interests and short positions
disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a
trust, the trustee(s),
settlor and beneficiaries must be named.
--------------------
(c) Name of offeror/offeree in relation to whose relevant Midatech Pharma plc
securities this form relates:
Use a separate form for each offeror/offeree
--------------------
(d) If an exempt fund manager connected with an offeror/offeree,
state this and specify identity
of offeror/offeree:
--------------------
(e) Date position held/dealing undertaken: 23/06/2020
For an opening position disclosure, state the latest practicable
date prior to the disclosure
--------------------
(f) In addition to the company in 1(c) above, is the discloser No
making disclosures in respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
--------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant
securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate)
for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to
which the disclosure relates following the dealing (if any)
Class of relevant security: 0.1p ordinary shares
Interests Short positions
----------------- ------------------
Number % Number %
---------- ------------- ---
(1) Relevant securities owned and/or controlled: 1,655,000 4.22 0
---------- ----- ------------- ---
(2) Cash-settled derivatives: 0
---------- ----- ------------- ---
(3) Stock-settled derivatives (including
options) and agreements to purchase/sell: 0
---------- ----- ------------- ---
TOTAL: 1,655,000 4.22 0
---------- ----- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements
to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror
or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
Class A 0.1p ordinary Buy 75,000 GBP 0.206
-------------- --------------------- ---------------
Class A 0.1p ordinary Buy 30,000 GBP 0.2055
-------------- --------------------- ---------------
Class A 0.1p ordinary Buy 25,000 GBP 0.2059
-------------- --------------------- ---------------
Class A 0.1p ordinary Buy 25,000 GBP 0.21
-------------- --------------------- ---------------
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per unit
relevant description e.g. reference
security e.g. CFD opening/closing a securities
long/short
position,
increasing/reducing
a long/short
position
None
--------------- -------------------- --------------- ---------------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry Option
relevant description purchasing, securities price e.g. date money
security e.g. call selling, to which per unit American, paid/
option varying option European received
etc. relates etc. per unit
None
------------ ------------ ----------- --------- ---------- ------- ---------
(ii) Exercise
Class of Product Exercising/ Number of Exercise price
relevant description exercised securities per unit
security e.g. call against
option
None
---------------- ---------------- ---------------- ----------------
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
None
------------------------ -------- -------------------------
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding,
formal
or informal, relating to relevant securities which may be an inducement to deal or
refrain
from dealing entered into by the person making the disclosure and any party to the
offer or
any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no
such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the
person
making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to
which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 24/06/2020
------------
Contact name: David Corben
------------
Telephone number*: 01727895135
------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RETKKQBPKBKDOAB
(END) Dow Jones Newswires
June 24, 2020 07:01 ET (11:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024